Contributions
Abstract: PB1410
Type: Publication Only
Session title: Acute myeloid leukemia - Clinical
Background
Acute myeloid leukemia is nowadays considered the most common acute leukemia in adults and the most common cause of leukemia-associated mortality in adults. Being a heterogeneous disease, patients can achieve complete hematological remission with bone marrow blasts <5% by intensive chemotherapy, but will eventually relapse due to the persistence of leukemic cells after chemotherapy unidentified by routine morphologic evaluation which is known as minimal residual disease.
Aims
To identify leukemia-associated immunophenotypes in sixty acute myeloid leukemia patients at diagnosis using an eight color multiparameter flow cytometry panel and to detect if they showed any alteration in relapse/refractory cases.
Methods
Eight color multiparameter flow cytometry panel with CD45/SSC log gating strategy was used for analysis of leukemia-associated immunophenotypes in bone marrow samples obtained from sixty consecutive , unselected acute myeloid leukemia patients presenting to Alexandria University Hospitals at diagnosis, relapse and refractory cases. Twenty bone marrow samples from patients performing bone marrow aspirate for non-malignant hematological indications and twenty regenerative bone marrow samples from acute lymphoblastic leukemia patients on chemotherapy in follow up of matched age and sex were included as controls.
Results
Leukemia-associated immunophenotypes were observed in 53 cases (88.3%). Only one aberrant immunophenotype was identified in five cases (8.3%), while two to twelve aberrant immunophenotypes were found in the other 48 cases (80%). Strong leukemia-associated immunophenotypes were obtained by the combination of CD2, CD4, CD56 with either CD34 or CD117, in contrast to CD19 which has to be combined with CD117. Refractory cases showed the presence of same leukemia-associated immunophenotypes at both initial diagnosis and persistent disease, while one of the relapsed cases showed acquisition of new leukemia-associated immunophenotypes after relapse.
Conclusion
The good choice of leukemia-associated immunophenotypes depends on their specificity rather than their frequency. The results of this study can help in increasing the sensitivity of leukemia-associated immunophenotypes strategy in minimal residual disease using multiparameter flowcytometry in acute myeloid leukemia patients which is considered an important post-diagnosis parameter associated with prognosis and clinical outcome.
Keyword(s): Acute myeloid leukemia, Flow cytometry, Leukemia-associated antigen, Minimal residual disease (MRD)
Abstract: PB1410
Type: Publication Only
Session title: Acute myeloid leukemia - Clinical
Background
Acute myeloid leukemia is nowadays considered the most common acute leukemia in adults and the most common cause of leukemia-associated mortality in adults. Being a heterogeneous disease, patients can achieve complete hematological remission with bone marrow blasts <5% by intensive chemotherapy, but will eventually relapse due to the persistence of leukemic cells after chemotherapy unidentified by routine morphologic evaluation which is known as minimal residual disease.
Aims
To identify leukemia-associated immunophenotypes in sixty acute myeloid leukemia patients at diagnosis using an eight color multiparameter flow cytometry panel and to detect if they showed any alteration in relapse/refractory cases.
Methods
Eight color multiparameter flow cytometry panel with CD45/SSC log gating strategy was used for analysis of leukemia-associated immunophenotypes in bone marrow samples obtained from sixty consecutive , unselected acute myeloid leukemia patients presenting to Alexandria University Hospitals at diagnosis, relapse and refractory cases. Twenty bone marrow samples from patients performing bone marrow aspirate for non-malignant hematological indications and twenty regenerative bone marrow samples from acute lymphoblastic leukemia patients on chemotherapy in follow up of matched age and sex were included as controls.
Results
Leukemia-associated immunophenotypes were observed in 53 cases (88.3%). Only one aberrant immunophenotype was identified in five cases (8.3%), while two to twelve aberrant immunophenotypes were found in the other 48 cases (80%). Strong leukemia-associated immunophenotypes were obtained by the combination of CD2, CD4, CD56 with either CD34 or CD117, in contrast to CD19 which has to be combined with CD117. Refractory cases showed the presence of same leukemia-associated immunophenotypes at both initial diagnosis and persistent disease, while one of the relapsed cases showed acquisition of new leukemia-associated immunophenotypes after relapse.
Conclusion
The good choice of leukemia-associated immunophenotypes depends on their specificity rather than their frequency. The results of this study can help in increasing the sensitivity of leukemia-associated immunophenotypes strategy in minimal residual disease using multiparameter flowcytometry in acute myeloid leukemia patients which is considered an important post-diagnosis parameter associated with prognosis and clinical outcome.
Keyword(s): Acute myeloid leukemia, Flow cytometry, Leukemia-associated antigen, Minimal residual disease (MRD)